This article needs to be updated. The reason given is: This is an ongoing event, as of this writing South Korea's infection rate is spiking, info in article is a year old.(March 2022)
|Date||26 February 2021 – present|
|Cause||COVID-19 pandemic in South Korea|
|Part of a series on the|
COVID-19 vaccination in South Korea is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
Daily updates are provided by Korea Disease Control and Prevention Agency.
As of 5 July 2021, due to vaccine shortages, the vaccination rate has been slowed down since 20 June. The vaccination rate remains 29% for more than two weeks.According to JoongAng Ilbo, as of 5 July, the remaining amount of the COVID-19 vaccine is 1.8 million doses, including 1.4 million from Pfizer.
On 6 July 2021, it is reported that South Korea has signed a deal with Israel to borrow 700,000 expiring doses of the Pfizer-BioNTech's vaccine. South Korea will return the same amount of vaccines to Israel around September or October of this year.
On 29 November 2021, President Moon Jae-in urged the rapid administration of booster shots against COVID-19, in response to an increased number of severe cases and deaths following the easing of anti-virus rules.
On 10 February 2021, South Korea granted its first approval of a COVID-19 vaccine to Oxford–AstraZeneca, allowing the two-shot regimen to be administered to all adults, including the elderly. The approval came with a warning, however, that consideration is needed when administering the vaccine to individuals over 65 years of age due to limited data from that demographic in clinical trials.
On 14 April 2021, The additional 250,000 doses of Pfizer/BioNTech vaccines arrived in the country.
On 3 June 2021, the United States donated one million doses of Johnson & Johnson's vaccine to South Korea. The United States initially announced to donate 550,000 doses to South Korean troops working in close contact with American forces.
On 19 August 2021, Romania decided to donate 450,000 expiring Moderna vaccines to South Korea.
|Vaccine dose||Progress||Doses ordered||Manufacturer||Remarks|
|Oxford-AstraZeneca||Approved for use||20 million||SK Bioscience||-|
|up to 2.6 million|| SK Bioscience|
|Pfizer–BioNTech||Approved for use||96 million||Pfizer||-|
|up to 0.4 million||Pfizer||COVAX|
|0.7 million||Pfizer||Vaccine swap from Israel|
|1 million||Pfizer||Vaccine swap from Romania|
|Janssen||Approved for use||6 million||Emergent BioSolutions||-|
|1.4 million||An offer from the United States|
|Moderna||Approved for use||40 million|| Lonza |
|0.4 million||Lonza||An offer from Romania|
|Novavax||Approved for use||40 million||SK Bioscience||-|
|Sputnik V||Pre-review||None||Hankook Korus Pharm||-|
|Oxford-AstraZeneca||SK Bioscience||4 January 2021||None||10 February 2021||26 February 2021|
|Catalent||4 January 2021||12 May 2021||21 May 2021||14 May 2021|
|Pfizer–BioNTech||Pfizer||25 January 2021||3 February 2021||5 March 2021||27 February 2021|
|Janssen||Emergent BioSolutions||27 February 2021||None||7 April 2021||10 June 2021|
|Moderna||Lonza||12 April 2021||None||21 May 2021||17 June 2021|
AstraZeneca signed a deal with South Korea's SK Bioscience to manufacture its vaccine products. The collaboration calls for the SK Bioscience to manufacture AZD1222 for local and global markets.The World Health Organization approved AstraZeneca's COVID-19 vaccine for emergency use on February. The initial approval covers doses produced by AstraZeneca and South Korea's SK Bioscience.
South Korea's Korus Pharm has formed a consortium to produce Russia's Sputnik V COVID-19 vaccine. the consortium will produce 500 million doses of the vaccine.However, The Sputnik V doses manufactured in South Korea are not for domestic use. The vaccine is to be exported to Russia and UAE.
Novavax will license out its NVX-CoV2373 vaccine technology to SK Bioscience for contract manufacturing purposes. SK Bioscience will manufacture 40 million doses of Novavax vaccines.
On 2 March 2022, SK Bioscience submitted investigational new drug for GBP510 COVID-19 vaccine candidate to Korea Ministry of Food and Drug Safety, for Phase III clinical trial. SK Bioscience plans its Phase III trial in form of comparative effectiveness clinical trial, targeting 4,000 people in South Korea.
|Vaccine||Type (technology)||Phase I||Phase II||Phase III|
|GX-19 (GX-19N)||DNA||Completed||In progress||In progress|
|EuCorVac-19||Subunit||Completed||In progress||Not Yet|
|AdCLD-CoV19||Viral vector||Completed||In progress||Not Yet|
|GLS-5310||DNA||Completed||In progress||Not Yet|
|NBP2001||Subunit||Completed||Not Yet||Not Yet|
|EG-COVID||mRNA||In progress||In progress||Not Yet|
|IN-B009||Subunit||In progress||Not Yet||Not Yet|
The Therapeutic Goods Administration (TGA) is the medicine and therapeutic regulatory agency of the Australian Government. As part of the Department of Health, the TGA regulates the quality, supply and advertising of medicines, pathology devices, medical devices, blood products and most other therapeutics. Any items that claim to have a therapeutic effect, are involved in the administration of medication, or are otherwise covered by the Therapeutic Goods Act 1989, the Therapeutic Goods Regulations 1990, or a ministerial order, must be approved by the TGA and registered in the Australian Register of Therapeutic Goods.
Serum Institute of India (SII) is an Indian biotechnology and biopharmaceuticals company, based in Pune. It is the world's largest manufacturer of vaccines. It was founded by Cyrus Poonawalla in 1966 and is a part of Cyrus Poonawalla Group.
The Oxford–AstraZeneca COVID-19 vaccine, codenamed AZD1222, and sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for prevention of COVID-19. Developed in the United Kingdom by the Oxford University and British-Swedish company AstraZeneca, using as a vector the modified chimpanzee adenovirus ChAdOx1. The vaccine is given by intramuscular injection. Studies carried out in 2020 showed that the efficacy of the vaccine is 76.0% at preventing symptomatic COVID-19 beginning at 22 days following the first dose, and 81.3% after the second dose. A study in Scotland found that, for symptomatic COVID-19 infection after the second dose, the vaccine is 81% effective against the Alpha variant, and 61% against the Delta variant.
The COVID-19 vaccination program in the Philippines is an ongoing mass immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
The general COVID-19 vaccination in Australia program began on 22 February 2021 in response to the COVID-19 pandemic, and will continue with the goal of vaccinating all willing Australians before 2022. Front-line workers and aged care staff and residents will be the first Australians to be inoculated, before a gradual phased release to less-vulnerable and lower-risk population groups throughout 2021. The Therapeutic Goods Administration (TGA) approved four vaccines for Australian use in 2021: the Pfizer–BioNTech vaccine on 25 January, the Oxford–AstraZeneca vaccine on 16 February, Janssen vaccine on 25 June and the Moderna vaccine on 9 August. Although approved for use, the Janssen vaccine is not included in the Australian vaccination program.
A dispute broke out in January 2021 between the European Commission and the pharmaceutical company AstraZeneca AB about the provision of COVID-19 vaccines during the COVID-19 pandemic, and, in February, spilled out into a dispute over Article 16 of the Northern Ireland Protocol. Vaccination proceeded apace in the UK but more slowly in the EU, and by the end of March 2021, over 30% of the UK population had received at least one dose of vaccine compared to about 8% of the EU population. This was partly due to limited availability of the AstraZeneca vaccine in the EU. The World Health Organization and the European Medicines Agency continued to state that the vaccine was safe and effective. However, a representative of the European Medicines Agency said in June that vaccines based on the mRNA technology should be preferred if available for all age groups, including for the over 60s.
The COVID-19 vaccination campaign in Albania is a mass immunization campaign that was put in place by the Albanian authorities in order to respond to the ongoing COVID-19 pandemic. It started on 11 January 2021.
COVID-19 vaccination in Canada is an ongoing, intergovernmental effort coordinated between the bodies responsible in the Government of Canada to acquire and distribute vaccines to individual provincial and territorial governments who in turn administer authorized COVID-19 vaccines during the COVID-19 pandemic in Canada. Provinces have worked with local municipal governments, hospital systems, family doctors and independently owned pharmacies to aid in part, or in full with vaccination rollout. The vaccination effort in full is the largest such immunization effort in the nation's history. The vaccination effort began December 14, 2020, and is currently ongoing.
COVID-19 vaccination in South Africa is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
COVID-19 vaccination programs have begun in many countries and territories in Africa. In June 2021, the World Health Organization predicted that 47 of Africa's 54 nations would fall short of the aim of vaccinating 10% of their people by September 2021. In June, Africa accounted for fewer than 1% of worldwide vaccine doses delivered.
The COVID-19 vaccination in Vietnam is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in response to the ongoing pandemic in the country. Following the approval of the Oxford–AstraZeneca COVID-19 vaccine on 30 January 2021, vaccinations commenced on 8 March 2021, and will continue throughout the year with the goal of vaccinating 80% of the population by June 2022. The Sputnik V was later approved for use on 23 March 2021. The Sinopharm BIBP vaccine was approved for emergency use on 4 June 2021, while Pfizer–BioNTech COVID-19 vaccine, Moderna COVID-19 vaccine and Janssen COVID-19 vaccine were approved on 12 June 2021, 29 June 2021, and 15 July 2021, respectively. Vietnam approved Abdala vaccine from Center for Genetic Engineering and Biotechnology on 18 September 2021, and Covaxin from Bharat Biotech on 10 November 2021.
COVID-19 vaccination in Mexico is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
The COVID-19 vaccination in Indonesia is an ongoing mass immunization in response to the COVID-19 pandemic in Indonesia. On 13 January 2021, the program commenced when President Joko Widodo was vaccinated at the presidential palace. In terms of total doses given, Indonesia ranks third in Asia and fifth in the world.
The COVID-19 vaccination program in Argentina is an ongoing effort of mass immunization. Vaccination against COVID-19 began in Argentina on 29 December 2020 aiming at health professionals. Argentina struck a deal with the United Kingdom in November 2020 for a British made vaccine produced by the pharmaceutical company AstraZeneca and the University of Oxford. The vaccines are part of a deal where Argentina received 22.4 million doses. During the first week, 39,599 doses were applied to health professionals.
Bangladesh began the administration of COVID-19 vaccines on 27th January 2021 while mass vaccination started on 7th February 2021.
COVID-19 vaccination in Japan started later than in most other major economies. The country has frequently been regarded as "slow" in its vaccination efforts.
COVID-19 vaccination in Sri Lanka is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, in response to the ongoing pandemic in the country. As of late July, the Sinopharm BIBP vaccine accounted for 78% of the total 13.8 million vaccines obtained by Sri Lanka to date. The United States donated over 1.5 million Moderna vaccine through COVAX.
COVID-19 vaccination in Taiwan is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in response to the ongoing pandemic in the country. Following the approval of the Oxford–AstraZeneca COVID-19 vaccine on 18 March 2021, vaccinations commenced on 22 March 2021, and will continue throughout the year with the goal of vaccinating 70% of the population by late October 2021.